Galimedix Establishes SAB in Advance of Phase 2 Study of GAL-101 for Dry AMD
Galimedix Therapeutics has formed a Scientific Advisory Board (SAB) to provide advice and direction to the company for the development of its compound GAL-101 for the treatment of dry age-related macular degeneration (AMD).
The SAB consists of retina experts from both clinical practice and academia with track records in the development of ophthalmic drugs. The advisors will consult with the company as it advances lead compound, GAL-101, as a potential eye drop treatment for dry AMD.
Scientific advisors include:
- Konstantinos Balaskas, MD, UCL Institute of Ophthalmology, London, UK
- Justis P. Ehlers, MD, Cole Eye Institute Cleveland Clinic, Cleveland, OH, USA
- Jeffrey S. Heier, MD, Ophthalmic Consultants of Boston, Boston, MA, USA
- Peter K. Kaiser, MD, Cole Eye Institute Cleveland Clinic, Cleveland, OH, USA
- Eleonora Lad, MD, PhD, Duke University Medical Center, Durham, NC, USA
- Ursula Schmidt-Erfurth, MD, Medical University of Vienna, Vienna, Austria
- Omer Trivizki, MD, MBA, Tel-Aviv Medical Center, Tel-Aviv, Israel
“We are excited to have such an esteemed group of international experts join our Scientific Advisory Board,“ Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix, said in a company news release. “The results our lead compound GAL-101 has shown in preclinical studies and in clinical phase 1 are encouraging and as we continue to move forward in advancing this drug candidate in the field of ophthalmology, the knowledge and expertise this group brings to Galimedix will be invaluable.”
A SAB meeting was held during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, on May 4, 2024. The company and the SAB agreed on the design, endpoints and selection criteria of the upcoming phase 2 DREAM study, which is expected to begin in late 2024.